Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
作者： Subrata Ghosh , Lianne S. Gensler , Zijiang Yang , Chris Gasink , Soumya D. Chakravarty
DOI: 10.1007/S40264-019-00797-3
关键词:
摘要: … oral IMMs or oral corticosteroids (CSs) during the psoriasis studies. Prior treatment with … integrated across indications, with no evidence of a dose effect in the occurrence of AEs, SAEs, …
springer.com
paperity.org参考文章(36)
Bruce Strober, Marc Chevrier, Matthias Augustin, Kim A Papp, Psolar investigators, Anil Londhe, Steve Calabro, PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. Journal of Drugs in Dermatology. ,vol. 11, pp. 1210- 1217 ,(2012)
W‐Q Li, J‐L Han, JE Manson, Eric Bruce Rimm, KM Rexrode, GC Curhan, AA Qureshi, None, Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. British Journal of Dermatology. ,vol. 166, pp. 811- 818 ,(2012) , 10.1111/J.1365-2133.2011.10774.X
KA1 Papp, CEM Griffiths, K Gordon, M Lebwohl, PO Szapary, Y Wasfi, D Chan, M‐C Hsu, V Ho, Pierre-Dominique Ghislain, B Strober, K Reich, PHOENIX 1, PHOENIX 2 and ACCEPT Investigators, Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. British Journal of Dermatology. ,vol. 168, pp. 844- 854 ,(2013) , 10.1111/BJD.12214
Richard B. Warren, Catherine H. Smith, Zenas Z.N. Yiu, Darren M. Ashcroft, Jonathan N.W.N. Barker, A. David Burden, Mark Lunt, Kathleen McElhone, Anthony D. Ormerod, Caroline M. Owen, Nick J. Reynolds, Christopher E.M. Griffiths, Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) Journal of Investigative Dermatology. ,vol. 135, pp. 2632- 2640 ,(2015) , 10.1038/JID.2015.208
Arthur Kavanaugh, Lluís Puig, Alice B. Gottlieb, Christopher Ritchlin, Shu Li, Yuhua Wang, Alan M. Mendelsohn, Michael Song, Yaowei Zhu, Proton Rahman, Iain B. McInnes, , Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Arthritis Care and Research. ,vol. 67, pp. 1739- 1749 ,(2015) , 10.1002/ACR.22645
Eric Sorenson, John Koo, Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic Journal of Dermatological Treatment. ,vol. 26, pp. 493- 501 ,(2015) , 10.3109/09546634.2015.1027167
R. Gniadecki, B. Bang, L.E. Bryld, L. Iversen, S. Lasthein, L. Skov, Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris British Journal of Dermatology. ,vol. 172, pp. 244- 252 ,(2015) , 10.1111/BJD.13343
John L. Langowski, Robert A. Kastelein, Martin Oft, Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends in Immunology. ,vol. 28, pp. 207- 212 ,(2007) , 10.1016/J.IT.2007.03.006
ANNE-MARIE TOBIN, DOUGLAS J. VEALE, OLIVER FITZGERALD, SARAH ROGERS, PAUL COLLINS, DONAL O’SHEA, BRIAN KIRBY, Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. The Journal of Rheumatology. ,vol. 37, pp. 1386- 1394 ,(2010) , 10.3899/JRHEUM.090822
David Gratton, Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Archives of Dermatology. ,vol. 147, pp. 1197- 1202 ,(2011) , 10.1001/ARCHDERMATOL.2011.161